Back to top

JNJ’s OTTAVA Robotics and Medtech Strategy Underpin Buy Rating and Unchanged $282 Price Target

Analyst Asad Haider of Goldman Sachs reiterated a Buy rating on Johnson & Johnson, retaining the price target of $282.00. Asad Haider has given his...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Johnson & Johnson (JNJ)